开元官网登录入口

China, Nanchang—November 8, 2021—Shanghai MicroPort MedBot(Group) Co., Ltd. (referred to as "MicroPort® MedBot®"), an independently developed surgical robotic system, the Toumai® Laparoscopic Surgical Robot (referred to as "Toumai® "), successfully launched its clinical trial at the First Affiliated Hospital of Nanchang University. This multidisciplinary, multicenter clinical trial is the first clinical trial of a domestic four-arm surgical robot conducted in Jiangxi Province and holds significant importance for the development of domestic surgical robots.

On November 11, 2021, Professor Taiyuan Li, Director of the Department of General Surgery at the First Affiliated Hospital of Nanchang University, operated the Toumai® to perform a rectal cancer radical surgery. Compared to manual operations and traditional laparoscopic minimally invasive surgeries, the surgical robot overcomes the limitations of human hands. With highly dexterous surgical instruments, it enables more flexible and precise surgical operations in confined anatomical spaces, thereby improving surgical precision. The surgical robot can also filter out tremors, suppressing or even eliminating inadvertent tremors at the instrument's end, ensuring surgical accuracy. With multi-arm operation, the robotic system allows the primary surgeon to independently control the laparoscope and assistive retraction instruments, intuitively realizing the intentions of the primary surgeon and enhancing surgical efficiency.

▲ DirectorTaiyuan Li and team

Using Toumai ® endoscopic surgical robot

Currently, Toumai® has officially launched multidisciplinary, multicenter clinical trials nationwide, being applied in clinical treatments in departments such as general surgery, thoracic surgery, and gynecology. This marks the capability of Chinese surgical robots to assist doctors in performing complex surgeries in narrow anatomical spaces.

Yu Liu, Chief Business Officer of MicroPort® MedBot®, stated, "We appreciate the support of the First Affiliated Hospital of Nanchang University for domestic surgical robots. Professor Li Taiyuan's rectal cancer radical surgery using the MicroPort® MedBot® robotic system fully demonstrates his superb clinical skills and professional competence. We look forward to further development through the multidisciplinary clinical trials of the MicroPort® TiMSTM robotic system at the First Affiliated Hospital of Nanchang University, promoting innovation and iteration of domestic robots, providing patients with minimally invasive, precise, and accessible medical services, and realizing our initial goal of 'making all surgeries possible.'"